financetom
Business
financetom
/
Business
/
GM beats Q3 revenue estimates, raises core profit guidance
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
GM beats Q3 revenue estimates, raises core profit guidance
Oct 21, 2025 4:09 AM

Overview

* GM Q3 2025 revenue beats analyst expectations despite slight yr/yr decline

* Adjusted EPS for Q3 2025 beats consensus, reflecting operational efficiency

* Adjusted EBIT for Q3 2025 exceeds analyst estimates, highlighting strong performance

Outlook

* GM raises 2025 EBIT-adjusted guidance to $12.0 bln-$13.0 bln

* GM expects 2025 adjusted core profit to be between $12.0 billion and $13.0 billion

* Company increases 2025 adjusted automotive free cash flow to $10.0 bln-$11.0 bln

* GM revises 2025 EPS-diluted-adjusted guidance to $9.75-$10.50

Result Drivers

* EV STRATEGIC REALIGNMENT - GM attributes Q3 results to strategic realignment of EV capacity and manufacturing footprint

* OPERATIONAL EFFICIENCY - GM cites operational efficiency as a driver for beating Q3 adjusted EPS estimates

* STRONG PERFORMANCE - GM's adjusted EBIT exceeded analyst estimates, highlighting strong performance

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $48.59 $45.26

Revenue bln bln (17

Analysts

)

Q3 Beat $2.80 $2.30

Adjusted (17

EPS Analysts

)

Q3 EPS $1.35

Q3 Net $1.32

Income bln

Q3 Beat $3.37 $2.72

Adjusted bln bln (15

EBIT Analysts

)

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 16 "strong buy" or "buy", 10 "hold" and 2 "sell" or "strong sell"

* The average consensus recommendation for the auto & truck manufacturers peer group is "hold."

* Wall Street's median 12-month price target for General Motors Co ( GM ) is $62.00, about 6.5% above its October 20 closing price of $58.00

* The stock recently traded at 6 times the next 12-month earnings vs. a P/E of 5 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Herc's Q3 Adjusted Earnings, Revenue Rise
Herc's Q3 Adjusted Earnings, Revenue Rise
Oct 22, 2024
06:51 AM EDT, 10/22/2024 (MT Newswires) -- Herc Holdings ( HRI ) reported Q3 adjusted earnings Tuesday of $4.35 per diluted share, up from $4 a year earlier. Analysts polled by Capital IQ expected $4.48. Total revenue for the quarter ended Sept. 30 was $965 million, up from $908 million a year earlier. Analysts surveyed by Capital IQ expected $931.3...
RTX boosts 2024 forecasts again on demand for aircraft repairs, defense systems
RTX boosts 2024 forecasts again on demand for aircraft repairs, defense systems
Oct 22, 2024
Oct 22 (Reuters) - RTX on Tuesday raised its 2024 adjusted profit and sales forecasts for the second time, citing strong demand for aircraft repairs and defense systems. The aerospace and defense giant expects full-year adjusted profit per share to be between $5.50 and $5.58, compared with its prior forecast range of $5.35 to $5.45. The company raised its revenue...
Market Chatter: Equinor Submits Bid for Japan Offshore Wind Lease
Market Chatter: Equinor Submits Bid for Japan Offshore Wind Lease
Oct 22, 2024
06:48 AM EDT, 10/22/2024 (MT Newswires) -- Equinor ( EQNR ) has submitted a bid alongside some Japanese partners in Japan's state auctions to develop an offshore wind farm, Reuters reported Tuesday, citing unnamed sources. Reuters said bidding for two sites totaling 1 gigawatt in prefectures Aomori and Yamagata closed in July, and winners are expected to be announced by...
Mangoceuticals 'Strongly Refutes' Eli Lilly's Claims About Copying Weight-Loss Drugs
Mangoceuticals 'Strongly Refutes' Eli Lilly's Claims About Copying Weight-Loss Drugs
Oct 22, 2024
06:48 AM EDT, 10/22/2024 (MT Newswires) -- Mangoceuticals ( MGRX ) said late Monday it strongly refutes Eli Lilly's ( LLY ) claims that the company improperly imitated its weight-loss Zepbound and Mounjaro medicines. MangoRx strongly refutes any and all claims made by Eli Lilly ( LLY ) regarding the sale of compounded tirzepatide, the company added. Eli Lilly (...
Copyright 2023-2026 - www.financetom.com All Rights Reserved